Utah Medical Products BTC-100 BT-Cath Balloon Tamponade Catheter for Postpartum Uterine Hemorrhage 1/EA

Utah Medical Products BTC-100 BT-Cath Balloon Tamponade Catheter for Postpartum Uterine Hemorrhage 1/EA

• Model: BTC-100

The BT‑Cath® (BTC‑100) is engineered as a life‑saving adjunct in the management of postpartum uterine hemorrhage when conservative measures such as uterine massage and uterotonic drugs fail to control bleeding. Upon insertion into the uterine cavity—ideally positioned at or near the fundus—the soft, contoured silicone balloon is inflated gradually to exert gentle compression against the uterine walls and the placental bed. At the same time, the secondary drainage lumen allows continuous monitoring of intrauterine bleeding via a connected drainage bag, giving clinicians real‑time feedback about hemostasis. This dual‑lumen design optimizes both tamponade effect and visible drainage measurement for timely decision‑making.

From a workflow standpoint, the BTC‑100 kit provides a ready‑to‑use solution: the inclusion of syringes and a bag‑spike allows rapid preparation and inflation of the balloon up to its 500 mL capacity when required. The latex‑free silicone construction minimises allergy risk. Clinicians are guided to inflate only to the volume necessary to achieve tamponade while monitoring pressure and drainage; over‑inflation or delayed removal beyond 24 hours are cautioned against due to risks such as uterine rupture or infection. The inclusion of check‑valves and a stopcock facilitates controlled inflation and deflation, helping the clinician manage the system safely.

For patients, the BT‑Cath® offers a minimally invasive alternative to immediate surgical or radiologic intervention in postpartum hemorrhage scenarios. Its insertable design means that, once properly placed, it can give the uterus time to contract and bleeding to subside without additional surgical trauma. However, it remains a temporising device—not a substitute for definitive treatment if bleeding persists or additional pathology (e.g., laceration, retained placenta, coagulopathy) is present. Close monitoring is essential, and the device should be removed once hemostasis is confirmed or by the 24‑hour mark to reduce infection risk.